Interventional Cardiology Devices Market (2026 - 2033) Size, Share & Trends Analysis Report By Product (Coronary Stents, PTCA Balloon Catheters), By Procedures (Coronary Artery Disease, Acute Myocardial Infarction), By End Use, By Region, And Segment Forecasts

Key Market Trends & Insights

• By product: Coronary stents segment led the market with the largest revenue share of 48.3% in 2025.
• By procedures: Coronary artery disease (CAD) segment held the largest revenue share of 52.2% in 2025.
• By end use: Hospital segment accounted for the largest market revenue share in 2025.

Regional Highlights

• Largest regional market: North America (46.1% revenue share, 2025)
• By country: The U.S. accounted for the largest market revenue share in North America in 2025.

Market Size & Forecast

• Market size in 2025: USD 11.3 Billion
• Estimated market size in 2026: USD 12.1 Billion
• Projected market size by 2033: USD 19.8 Billion
• CAGR (2026-2033): 7.3%

In October 2024, the CDC reported 919,032 U.S. deaths from cardiovascular disease in 2023, with coronary heart disease causing 371,506 deaths.

About 1 in 6 CVD deaths occurred in adults under 65, and approximately 805,000 heart attacks happened nationwide, including 605,000 first-time events.

Market Drivers

Increasing Product Innovations and Regulatory Approvals

The growth of the interventional cardiology devices industry is primarily driven by advancements in product innovation and regulatory approvals. Manufacturers are investing heavily in next-generation stents, catheters, guidewires, and imaging systems to improve procedural outcomes and reduce complications. Innovations such as drug-eluting stents with bioresorbable polymers, thinner strut designs, and improved deliverability are enhancing safety and efficacy in percutaneous interventions. In May 2025, Shockwave Medical, part of Johnson & Johnson MedTech, presented data from 23 studies at EuroPCR 2025, highlighting the use of intravascular lithotripsy (IVL) and Reducer technology in PCI procedures. Key presentations included the EMPOWER CAD study on women with calcified coronary arteries and the BALI trial comparing IVL to conventional lesion preparation, underscoring IVL’s role in managing calcified coronary lesions and improving PCI outcomes.

Increasing Adoption of Minimally Invasive Cardiovascular Procedures

The increasing adoption of minimally invasive cardiovascular procedures is a key driver of the interventional cardiology devices industry. Procedures such as percutaneous coronary interventions (PCI), transradial access interventions, and catheter-based therapies are preferred over open-heart surgeries due to lower complication rates, reduced blood loss, and shorter recovery times, boosting hospital adoption of advanced stents, guidewires, and imaging catheters. In May 2025, SCAI News reported that a single-center study of 677 patients undergoing chronic total occlusion percutaneous coronary intervention found that stenting, a minimally invasive interventional cardiology procedure, improved long-term outcomes, with lower six-month cardiovascular mortality and a reduced incidence of cardiac arrest at one year compared to non-stented cases.

“While stenting is widely accepted as beneficial for patients with total blockages, the data presented at SCAI Scientific Sessions provides further evidence that it should be considered safe and effective in the long term.”

- MD, MPH, FACC, FSCAI, Clinical Associate Professor of Medicine at Wayne State University School of Medicine, Medical Director Cardiac Catheterization Lab at Detroit Medical Center in Detroit, Mich., and lead author.

Rising Volume of Percutaneous Coronary Intervention (PCI) Procedures

The growing number of percutaneous coronary intervention (PCI) procedures significantly contributes to the interventional cardiology devices industry. PCI is a common method for addressing coronary artery disease by improving blood flow in narrowed or obstructed coronary arteries. The rising incidence of cardiovascular conditions, such as coronary artery disease and acute coronary syndromes, is leading to an increase in patients needing interventional treatment, providing a new alternative in addition to guideline-directed medical therapy for this high-demand patient demographic.

In May 2025, the SCAI Scientific Sessions reported that 408,060 outpatient PCI procedures (2020-2022) were analyzed, with 1.8% performed in ambulatory surgery centers and 98.2% in hospital outpatient departments. PCI use in ASCs rose to 0.87 per 10,000 person‑years, and 30‑day adverse events, including mortality, stroke, and bleeding, remained below 2%.

Funding and Strategic Investments in Interventional Cardiology Devices Market

Market Concentration & Characteristics

The chart below represents the relationship between industry concentration, industry characteristics, and industry participants. There is a medium-high degree of innovation, a moderate level of merger & acquisition activities, a medium impact of regulations, and moderate expansion of the industry.

The interventional cardiology devices industry exhibits a medium-high level of technological innovation, driven by ongoing product introductions and innovations focused on improving cardiovascular treatment outcomes. Manufacturers are launching cutting-edge devices such as left atrial appendage (LAA) exclusion systems, sophisticated stents, and less invasive cardiac implants to improve the safety and efficacy of procedures. For instance, in November 2023, Medtronic launched its Penditure Left Atrial Appendage (LAA) Exclusion System in the U.S. This launch was expected to expand Medtronic’s Cardiac portfolio and offer surgeons a new option for LAA management during heart surgeries.

Mergers and acquisitions activity is moderate, primarily focused on several key players acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies. In February 2026, Boston Scientific Corporation announced its USD 14.5 billion acquisition of Penumbra, expanding its vascular and neurovascular portfolios to include new treatments for pulmonary embolism, stroke, deep vein thrombosis, and other cardiovascular conditions.

The regulatory environment for interventional cardiology devices combines stringent oversight with increasingly streamlined approval pathways, particularly through the U.S. Food and Drug Administration and CE marking, enabling faster market access for innovative technologies. Recent approvals of advanced stents, physiology-guided tools, and intravascular imaging catheters have expanded treatment options for complex coronary conditions. Moreover, strict regulatory compliance ensures high safety and efficacy standards, strengthening clinician trust and accelerating adoption across hospitals and cardiac care centers.

Product expansion is low to moderate. For instance, in October 2025, Terumo Interventional Systems obtained FDA 510(k) clearance for the OPUSWAVE Dual Sensor Imaging System along with the DualView imaging catheter. This platform combines OFDI and IVUS in a single catheter, allowing thorough evaluation of coronary artery disease and offering the potential to streamline PCI procedures by reducing both time and costs.

Regional expansion is significant, with companies actively targeting underserved markets across Asia Pacific, the Middle East, and Latin America. Key players leverage this strategy to enhance their product capabilities and expand the reach of their product offerings. In December 2025, Terumo Health Outcomes partnered with Medis Medical Imaging in the U.S. and integrated ePRISM and QFR technologies to enhance non-invasive coronary assessment. The collaboration aims to improve procedural efficiency, clinical decision-making, and patient outcomes

Product Insights

The coronary stents segment led the market with the largest revenue share of 48.3% in 2025. This growth is attributed to rapid advancements in stent technology, the rising prevalence of CVDs, and the increasing adoption of minimally invasive procedures. For instance, in August 2024, Medtronic introduced its latest drug-eluting coronary stent, the Onyx Frontier DES, after receiving the CE Mark. This innovative stent features an enhanced delivery system built upon the successful Resolute Onyx DES platform.

The accessory devices segment is expected to grow at the fastest CAGR over the forecast period. Rising CVD cases and the launch of technologically advanced products drive the market's growth. For instance, in October 2025, Terumo India launched the FineCross M3 Coronary Micro-Guide Catheter in India to support complex percutaneous coronary intervention (PCI) procedures. The device is designed to enhance guidewire support, lesion crossability, and navigation through tortuous coronary vessels, helping physicians manage challenging coronary lesions more effectively.

Procedure Insights

The coronary artery disease (CAD) segment led the market with the largest revenue share of 52.2% in 2025.  The segment growth is driven by the need to restore coronary blood flow and reduce the risk of adverse cardiovascular events. In August 2024, an article published in Medicina (Kaunas) discussed advances and ongoing challenges in interventional cardiology for coronary artery disease, highlighting the evolution of PCI, imaging techniques such as IVUS and OCT, and device innovations, including second-generation DES, bioresorbable scaffolds, and drug-eluting balloons. The review emphasized strategies to manage restenosis, stent thrombosis, and complex lesions, and evidence from key trials guiding optimal revascularization in both acute and stable CAD patients.

The chronic total occlusion (CTO) segment is anticipated to grow at the fastest CAGR over the forecast period. The segment growth is driven by the need to restore perfusion in patients with refractory angina or ischemia despite optimal medical therapy. CTO procedures aim to improve symptoms, exercise tolerance, and long-term cardiac function. Success depends on specialized operator expertise and advanced crossing techniques. In November 2025, the European Heart Journal reported trends in PCI for long chronic total occlusions (CTOs, ≥20 mm) from 10,302 Japanese patients (54.6% with long CTOs). Reverse CART had the highest technical success rate (94.7%), but longer guidewire crossing time (124 minutes) and a higher rate of coronary perforation (8.5%). Over time, antegrade wiring and IVUS-guided wiring increased for favorable distal anatomy, while primary retrograde and reverse CART declined, reflecting procedural optimization based on lesion characteristics.

End Use Insights

The hospitals segment led the market with the largest revenue share of 70.8% in 2025, driven by the high complexity of cases, including multivessel coronary disease, acute myocardial infarction, and chronic total occlusions, which require rapid intervention and continuous monitoring. Hospitals provide integrated care pathways that combine diagnosis, intervention, and post-procedural management under one roof. In December 2025, St. Francis Hospital & Heart Center began using the Acolyte OCT-guided re-entry catheter system for a chronic total occlusion PCI study, becoming the third center worldwide to do so. The system uses intravascular imaging to improve guidewire placement and procedural safety in patients with persistent symptoms despite medical therapy.

The ambulatory surgical centers segment is estimated to register at the fastest CAGR over the forecast period.The segment is driven by the shift toward minimally invasive therapies, cost containment, and patient preference for shorter hospital stays. ASCs facilitate efficient patient flow while maintaining high standards of procedural safety and recovery. In February 2026, an article published in Ambulatory Surgery Center News highlighted that select ambulatory surgery centers (ASCs) performing percutaneous coronary interventions reported complication rates comparable to hospitals at about 1%, while achieving cost savings of roughly USD 4,000 per procedure, emphasizing the potential for safe and more efficient cardiac care in the ASC setting.

Regional Insights

North America dominated the global interventional cardiology devices market with the largest revenue share of 46.1% in 2025. Rising prevalence of cardiovascular diseases, rising adoption of minimally invasive procedures, and strategic initiatives by the key players. In November 2025, the Merck Foundation launched the Collaborative for Equity in Cardiac Care, a USD 22 million, five-year initiative to improve access to high-quality cardiovascular services in the U.S. Grants were awarded to 11 organizations, including Capital Health System, MedNorth Health Center, and the University of Chicago, to implement programs addressing gaps in timely cardiac care and improving outcomes in underserved communities.

U.S. Interventional Cardiology Devices Market Trends

The interventional cardiology devices market in the U.S. accounted for the largest market share in North America in 2025, driven by growing awareness among patients and healthcare providers of the importance of early diagnosis and intervention, which is further increasing procedure volumes across hospitals, specialty cardiac centers, and outpatient facilities. In April 2024, Michigan Medicine reported that over 500,000 Americans undergo percutaneous coronary intervention (PCI) annually. PCI carries a 1-2% risk of death, with around 10% of these considered potentially preventable. The study stressed strategies to reduce avoidable mortality during PCI.

Europe Interventional Cardiology Devices Market Trends

The interventional cardiology devices market in Europe is expected to grow significantly over the forecast period. Hospitals are integrating advanced technologies such as drug-eluting stents, high-performance PTCA balloon catheters, intravascular ultrasound, and optical coherence tomography to improve lesion assessment and optimize stent deployment. In February 2026, an article published in the European Heart Journal discussed the future of coronary revascularization, highlighting a potential shift from traditional metallic coronary stents toward “metal-less” treatment strategies. The study emphasized advances in imaging, AI-guided diagnostics, and plaque-regression therapies that may reduce reliance on permanent stent implants while improving personalized treatment for coronary artery disease.

The UK interventional cardiology devices market is expected to grow at a substantial CAGR during the forecast period,driven bygrowing awareness among patients and clinicians of the importance of early detection and intervention, which is expanding procedure volumes in NHS hospitals and specialty cardiac centers. In June 2024, an article published in the journal BMJ examined cardiovascular disease trends among 22 million individuals in the UK. The study found that the incidence of major atherosclerotic conditions, such as coronary heart disease and stroke, declined by about 30%, while cases of arrhythmias, valve diseases, and thromboembolic conditions increased, keeping the overall cardiovascular disease burden relatively stable.

The interventional cardiology devices market held a significant share in Europe in 2025, driven by high prevalence of cardiovascular diseases, including coronary artery disease and peripheral arterial disease, which drives demand for interventional cardiology procedures, in December 2025, data from the Robert Koch Institute reported that 119,795 deaths from coronary heart disease (CHD) occurred in Germany in 2023, corresponding to an age-standardized mortality rate of 120 per 100,000 people. Mortality was significantly higher in men (172 per 100,000) than in women (82.2 per 100,000), with rates increasing sharply with age, reaching 1,476 per 100,000 among individuals aged 80 years and older.

Asia Pacific Interventional Cardiology Devices Market Trends

The interventional cardiology devices market in the Asia Pacific is expected to register at the fastest CAGR over the forecast period, driven by the high geriatric population, growing risk of heart diseases, and technological advancements in the region, which are factors contributing to market growth. Companies in the Asia-Pacific region, particularly in Japan, South Korea, China, and India, have been developing innovative interventional cardiology devices. These include advanced stents, catheters, balloons, and imaging technologies used in procedures such as angioplasty & stent placement. In October 2025, Cureus reported a post-market evaluation of the Pipit-NC PTCA balloon catheter in 87 PCI patients in India. During 134 balloon uses, including calcified, chronic total occlusion, and tortuous lesions, the device achieved complete procedural and device success without any in-hospital complications, confirming its effectiveness in complex coronary cases.

The China interventional cardiology devices market is anticipated to register significant growth during the forecast period. This is driven by the increasing use of minimally invasive coronary interventions for the management of complex lesions, chronic total occlusions, and calcified arteries, which is contributing to sustained growth in interventional cardiology procedure volumes. In October 2025, MicroPort Scientific Corporation reported that its coronary stent systems had exceeded 10 million units in both global shipments and implantations, marking a major international milestone. The company emphasized its clinical innovations, including Firehawk Liberty and Firesorb, and noted widespread adoption across more than 90 countries, with substantial hospital coverage in China.

The interventional cardiology devices market in Japanis anticipated to register at a substantial CAGR during the forecast period. Hospitals and specialty cardiac centers widely adopt minimally invasive coronary interventions to manage complex lesions and acute cardiac conditions, supported by strong clinical expertise and established catheterization laboratory infrastructure. In March 2024, a Journal of Cardiology review reported Japan’s age-adjusted heart disease mortality at 62.0 per 100,000 men and 31.3 per 100,000 women, with acute myocardial infarction at 12.9 and 4.6, respectively. Stroke mortality also declined, with cerebrovascular disease rates at 33.2 per 100,000 men and 18.0 per 100,000 women. Regional myocardial infarction incidence ranged from 51 in Yao City, Osaka, to 23.7 in Fukushima Prefecture.

Latin America Interventional Cardiology Devices Market Trends

The interventional cardiology devices market in Latin America is growing. Companies are introducing innovative devices such as DESs, balloons, and imaging technologies, catering to the region's increasing demand for advanced cardiovascular treatments. For instance, in March 2024, Boston Scientific Corporation secured approval from the U.S. FDA for its AGENT DCB designed to address coronary In-Stent Restenosis (ISR) in individuals with coronary artery disease. ISR entails the blockage or constriction of a stented vessel due to plaque or scar tissue. The AGENT DCB is now available in Latin America for managing patients with ISR and untreated small-vessel coronary disease.

The Brazil interventional cardiology devices marketis anticipated to register at a significant CAGR during the forecast period, driven by the rising incidence of coronary artery disease and acute myocardial infarction, which are major causes of hospitalization and increasing the need for catheter-based coronary revascularization procedures. Moreover, the large tertiary hospitals and cardiac centers in cities such as São Paulo and Rio de Janeiro perform significant volumes of percutaneous coronary interventions.

Middle East & Africa Interventional Cardiology Devices Market Trends

The interventional cardiology devices market in the Middle East and Africais anticipated to grow at a rapid CAGR over the forecast period. The growth in this region is driven by the increasing prevalence of CVDs and the growing adoption of minimally invasive procedures. The region has a high burden of CVDs, including conditions that increase the risk of stroke, making interventional cardiology devices a valuable treatment option.

The South Africa interventional cardiology devices market is anticipated to register at a considerable CAGR over the forecast period, as the market is supported by the rising burden of cardiovascular diseases, including coronary artery disease and acute myocardial infarction. Urbanization, lifestyle changes, and increasing prevalence of risk factors such as hypertension, diabetes, and obesity are contributing to a growing patient pool requiring diagnostic angiography and percutaneous coronary interventions.

Recent Developments

• In February 2026, ACIST Medical Systems, part of the Bracco Group, introduced the ACIST Pro Diagnostic System in select European markets. This advanced variable-rate contrast management system enhances precision, safety, and efficiency for image-guided cardiovascular procedures.

• In September 2025, Cook and Siemens Healthineers partnered to develop an integrated Interventional MRI (iMRI) suite, providing MRI-guided, radiation-free imaging for structural heart procedures. The system, still under development, is designed to enhance precision in minimally invasive cardiac interventions while eliminating ionizing radiation for patients and clinicians.

• In May 2025, Terumo Interventional Systems announced the commercial availability of its ROADSAVER carotid stent system. The device is designed to provide reliable support and safety during carotid artery interventions, enhancing procedural outcomes for patients at risk of stroke. 

Interventional Cardiology Devices Market Report Scope

Global Interventional Cardiology Devices Market Report Segmentation

This report forecasts revenue growth and provides, at the global, regional, and country levels, an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global interventional cardiology devices market report based on product, procedure, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Coronary Stents

    • Drug-Eluting Stents (DES)

    • Bare Metal Stents (BMS)

    • Bioresorbable Scaffolds (BRS)

  • PTCA Balloon Catheters

    • Normal

    • Specialty

    • Drug-Coated

  • Intravascular Imaging Catheters and Pressure Guidewires

  • Accessory Devices

    • PTCA Guidewires

    • PTCA Guiding

    • Catheters

    • Introducer Sheaths

• Procedure Outlook (Revenue, USD Million, 2021 - 2033)

  • Coronary Artery Disease (CAD)

  • Acute Myocardial Infarction (AMI)

  • Chronic Total Occlusion (CTO)

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Cath Labs

  • Ambulatory Surgical Centers (ASCs)

  • Specialty Cardiac Centers

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait